Current Opinion in Cardiology was launched in 1985. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of cardiology is divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Dr Sherif Nagueh has a longstanding interest in the evaluation of cardiac function, particularly left ventricular diastolic function. He was the chair of the writing group for the ASE/EAE guidelines on the echocardiographic evaluation of left ventricular diastolic function. He has done extensive research in the diagnosis and management of patients with myocardial diseases, especially dilated and hypertrophic cardiomyopathy and he was the chair of the multimodality imaging guidelines for patients with hypertrophic cardiomyopathy. Dr Nagueh serves as director of the Echocardiography Laboratory at the Houston Methodist DeBakey Heart & Vascular Center.
He has several clinical studies looking at left ventricular diastolic function in patients with and without heart failure and hypertrophic cardiomyopathy.
In addition to his clinical and research work, Dr Nagueh is a devoted educator, and has won numerous teaching awards. He has taught principles and clinical applications of echocardiography to cardiology fellows and sonographers for two decades. His lectures cover topics such as the use of doppler for calculation of flow and pressure gradients, assessment of left ventricular diastolic function, and echocardiographic assessment of patients with hypertrophic cardiomyopathy. As part of his commitment to education, Dr Nagueh serves as a board member, editor, and peer reviewer for many cardiology publications. He has published extensively in leading cardiology journals and has also contributed numerous textbook chapters.
Andrew L. Pipe
Dr Andrew L. Pipe graduated from Queen's University in 1974. Currently Chief of the Division of Prevention and Rehabilitation at the University of Ottawa Heart Institute, Dr Pipe is a Professor in the Faculty of Medicine at the University of Ottawa.
He is currently involved in clinical research assessing new approaches to smoking cessation, strategies designed to facilitate exercise adoption, and novel initiatives to prevent cardiovascular disease.
Dr Pipe has addressed audiences in over 30 nations and is frequently consulted on issues related to tobacco use and smoking cessation, drug use in sport, and physical activity and health.
In addition to his clinical responsibilities, Dr Pipe has been extensively involved in sports and sport medicine for many years. Dr Pipe served as a physician at 12 Olympic Games and has been the Team Physician for Canada's National Men's Basketball Team since 1978. A member of the Canadian Olympic Hall of Fame (Builder), he served as Chair of the Canadian Centre for Ethics in Sport from its inception until 2003.
Dr Pipe is the recipient of the International Olympic Committee's Award for “Sport, Health and Wellbeing” and honourary degrees from Queen's University (LLD), Brock University (DSc) and University of Guelph (DSc). He was formerly Vice Chairman of the Board of Trustees at Queen's University. In 2002 he was named to the Order of Canada.
Bobby Yanagawa is a surgeon in the Division of Cardiac Surgery, St Michael's Hospital. He is an Assistant Professor, Division of Cardiac Surgery at the University of Toronto. Dr Yanagawa obtained his BSc and PhD from the University of British Columbia and his MD degree and Cardiac Surgery Residency from the University of Toronto. He has completed research fellowships at the University of Wales College of Medicine (Cardiff, UK), National Cardiovascular Center (Osaka, Japan) and at St Michael's Hospital (Toronto, Canada). He completed a clinical fellowship at Mount Sinai Hospital, New York. His clinical and research interests are in arterial revascularization and valvular surgery. Dr Yanagawa currently maintains a translational science laboratory focused on the pathogenesis of valvular heart disease. He has published over 55 peer reviewed papers, 29 reviews and 15 book chapters. He has published in Nature Communications, Nature Medicine, Circulation, Journal of Thoracic and Cardiovascular Surgery and Annals of Thoracic Surgery. He was the AATS 13th Annual C. Walton Lillehei Award winner in 2010.
Dr Subodh Verma is a cardiac surgeon-scientist at St Michael's Hospital, Professor at the University of Toronto and the Canada Research Chair in Atherosclerosis. He has received the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is a member of the American Association of Thoracic Surgeons (AATS) and the College of New Scholars, Artists and Scientists, Royal Society of Canada. Dr Verma has an h-index of 61, with 15,029 total citations to 289 publications.
Dr Verma's has co-authored two state-of-the-art NEJM reviews on mitral valve repair and bicuspid aortopathy. His meta-analysis revealing that coronary artery bypass surgery is superior to angioplasty in patients with diabetes has been used by the American College of Cardiology and the Canadian Cardiovascular Society (CCS) to shape the recommendations for best revascularization choice in individuals with diabetes. He is a past/present contributor to several CCS guidelines as well as the next updates of the Canadian Diabetes Association guidelines and the AATS Consensus Guidelines on bicuspid aortic valverelated aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.
Dr Verma sits on the steering committees of the EMPEROR-Reduced and EMPEROR-Preserve trials and is a national lead investigator of the Dapa-HF trial. He spearheads the CARDIOLINK clinical trials platform at St. Michael's Hospital which conducts studies on cerebral protection during aortic surgery (ACE), mitral valve repair (CAMRA) and post-cardiac surgery atrial fibrillation (SEARCH-AF). Trials on secondary prevention in diabetes patients, anticoagulation therapy for bioprosthetic heart valves and anti-inflammatory management of critical limb ischemia are in the pipeline.
Dr Verma also oversees a pre-clinical research team that focuses on identifying novel biomarkers in cardiovascular health and developing innovative cardiovascular remedies. This research program has yielded 2 United States patents and is supported by the Canadian Foundation for Innovation, Canadian Institutes of Health Research and Heart & Stroke Foundation.